Skip to main content
Signal8

enVVeno Medical Corp (NVNO) Form 10-Q — Oct 29, 2026

$NVNOForm 10-QFiled Oct 29, 2026, 4:05 PM ET0001493152-26-049269Original filing

enVVeno Medical filed its Q3 2026 10-Q reporting a Q3 net loss of $4.4 million, a slight improvement from $4.5 million a year ago, with nine-month losses narrowing 25% to $11.8 million on lower SG&A and VenoValve study costs. The company holds $18.5 million in cash and investments and guided that burn will rise to $4-5 million per quarter in H1 2027 as the TAVVE pivotal trial for the enVVe System launches — funding operations only into Q4 2027. With no revenue and an explicit need to raise additional capital, the equity story hinges on the FDA IDE-approved TAVVE study (10-patient safety stage starting Q4 2026, then 220 patients at up to 40 U.S.

Key figures

Total Debt
0
Total Assets
19489000
Cash Position
2585000
Shares Outstanding
694826
Runway guidance
sufficient cash and investments to fund operations into the fourth quarter of 2027
Reverse split ratio
1:35 (effective January 20, 2026)
Working capital usd
16400000
Cash and investments usd
18500000
Burn rate per quarter usd
approximately $3-4 million, expected to rise to $4-5 million in H1 2027
Rd expense nine months usd
7063000
Sga expense nine months usd
5329000
Atm proceeds nine months usd
313000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.